1
|
Ambrus M, Fodor E, Berki T, Müller V, Uhlár Á, Hornyák I, Lacza Z. Professional Athletes Maintain High TNF-Alpha or IFN-Gamma Related Inflammatory Status after Recovering from COVID-19 Infection without Developing a Neutralizing Antibody Response. Sports (Basel) 2023; 11:sports11050097. [PMID: 37234053 DOI: 10.3390/sports11050097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Revised: 04/25/2023] [Accepted: 04/26/2023] [Indexed: 05/27/2023] Open
Abstract
INTRODUCTION Professional athletes are endangered by COVID-19 and belong to the high-risk population due to their lifestyle. To obtain information on the behavior of COVID-19 in professional athletes, serological, cytokine, and virus neutralization capacities were analyzed. MATERIALS AND METHODS Hungarian national teams participated in international sports events during the early phases of the COVID-19 epidemic in 2020. Altogether, 29 professional athletes volunteered to donate plasma. Their serological status was evaluated by IgA, IgM, and IgG ELISAs and the highest virus neutralization titer in an in vitro live tissue assay. Plasma cytokine patterns were analyzed with a Bioplex multiplex ELISA system. RESULTS Surprisingly, only one athlete (3%) had anti-SARS-CoV-2 IgG, while IgA was more common (31%). Neither plasma showed direct virus neutralization in a titer over 1:10; hence, they were not suitable for reconvalescent treatment. The 'cytokine storm' markers IL-6 and IL-8 were at baseline levels. In contrast, either the TNF-alpha-related cytokines or the IFN-gamma-associated cytokines were elevated. There was a strong negative correlation between the TNF-alpha- or IFN-gamma-related cytokines. CONCLUSIONS Professional athletes are susceptible to the SARS-CoV-2 infection without developing long-term immunity through neutralizing immunoglobulins. Elevated secretory and cellular immunity markers indicate that these systems are probably responsible for virus elimination in this subpopulation.
Collapse
Affiliation(s)
- Mira Ambrus
- Research Center for Sport Physiology, Hungarian University of Sports Sciences, 1123 Budapest, Hungary
| | - Eszter Fodor
- Research Center for Sport Physiology, Hungarian University of Sports Sciences, 1123 Budapest, Hungary
| | - Timea Berki
- Department of Immunology and Biotechnology, Faculty of Medicine, University of Pécs, 7624 Pécs, Hungary
| | - Veronika Müller
- Clinic of Pulmonology, Semmelweis University, 1083 Budapest, Hungary
| | - Ádám Uhlár
- Research Center for Sport Physiology, Hungarian University of Sports Sciences, 1123 Budapest, Hungary
| | - István Hornyák
- Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary
| | - Zsombor Lacza
- Research Center for Sport Physiology, Hungarian University of Sports Sciences, 1123 Budapest, Hungary
- Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary
| |
Collapse
|
2
|
Thümmler L, Konik M, Lindemann M, Fisenkci N, Koldehoff M, Gäckler A, Horn PA, Theodoropoulos F, Taube C, Zettler M, Anastasiou OE, Braß P, Jansen S, Witzke O, Rohn H, Krawczyk A. Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment. Front Immunol 2022; 13:980698. [PMID: 36311723 PMCID: PMC9606643 DOI: 10.3389/fimmu.2022.980698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Accepted: 09/26/2022] [Indexed: 11/17/2022] Open
Abstract
Immunocompromised patients are at increased risk for a severe course of COVID-19. Treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with anti-SARS-CoV-2 monoclonal antibodies (mAbs) has become widely accepted. However, the effects of mAb treatment on the long-term primary cellular response to SARS-CoV-2 are unknown. In the following study, we investigated the long-term cellular immune responses to SARS-CoV-2 Spike S1, Membrane (M) and Nucleocapsid (N) antigens using the ELISpot assay in unvaccinated, mAb-treated immunocompromised high-risk patients. Anti-SARS-CoV-2 mAb untreated though vaccinated COVID-19 immunocompromised patients, vaccinated SARS-CoV-2 immunocompromised patients without COVID-19 and vaccinated healthy control subjects served as control groups. The cellular immune response was determined at a median of 5 months after SARS-CoV-2 infection. Our data suggest that immunocompromised patients develop an endogenous long-term cellular immune response after COVID-19, although at low levels. A better understanding of the cellular immune response will help guide clinical decision making for these vulnerable patient cohorts.
Collapse
Affiliation(s)
- Laura Thümmler
- Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
- Institute for Transfusion Medicine, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Margarethe Konik
- Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Monika Lindemann
- Institute for Transfusion Medicine, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Neslinur Fisenkci
- Institute for Transfusion Medicine, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Michael Koldehoff
- Department of Hematology and Stem Cell Transplantation, University Medicine Essen, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- Department of Hygiene and Environmental Medicine, University Medicine Essen, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Anja Gäckler
- Department of Nephrology, University Medicine Essen, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Peter A. Horn
- Institute for Transfusion Medicine, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Fotis Theodoropoulos
- Department of Pneumology, University Medicine Essen-Ruhrlandklinik, University Duisburg- Essen, Essen, Germany
| | - Christian Taube
- Department of Pneumology, University Medicine Essen-Ruhrlandklinik, University Duisburg- Essen, Essen, Germany
| | - Markus Zettler
- Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Olympia Evdoxia Anastasiou
- Institute for Virology, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Peer Braß
- Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Sarah Jansen
- Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Oliver Witzke
- Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Hana Rohn
- Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
- *Correspondence: Adalbert Krawczyk, ; Hana Rohn,
| | - Adalbert Krawczyk
- Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
- Institute for Virology, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany
- *Correspondence: Adalbert Krawczyk, ; Hana Rohn,
| |
Collapse
|
3
|
Farhangnia P, Dehrouyeh S, Safdarian AR, Farahani SV, Gorgani M, Rezaei N, Akbarpour M, Delbandi AA. Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. Int Immunopharmacol 2022; 109:108786. [PMID: 35483235 PMCID: PMC9021130 DOI: 10.1016/j.intimp.2022.108786] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Revised: 04/14/2022] [Accepted: 04/16/2022] [Indexed: 12/15/2022]
Abstract
In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, causing a global pandemic called COVID-19. Currently, there is no definitive treatment for this emerging disease. Global efforts resulted in developing multiple platforms of COVID-19 vaccines, but their efficacy in humans should be wholly investigated in the long-term clinical and epidemiological follow-ups. Despite the international efforts, COVID-19 vaccination accompanies challenges, including financial and political obstacles, serious adverse effects (AEs), the impossibility of using vaccines in certain groups of people in the community, and viral evasion due to emerging novel variants of SARS-CoV-2 in many countries. For these reasons, passive immunotherapy has been considered a complementary remedy and a promising way to manage COVID-19. These approaches arebased on reduced inflammation due to inhibiting cytokine storm phenomena, immunomodulation,preventing acute respiratory distress syndrome (ARDS), viral neutralization, anddecreased viral load. This article highlights passive immunotherapy and immunomodulation approaches in managing and treating COVID-19 patients and discusses relevant clinical trials (CTs).
Collapse
Affiliation(s)
- Pooya Farhangnia
- Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States
| | - Shiva Dehrouyeh
- Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States
| | - Amir Reza Safdarian
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States; Department of Pathology, School of Medicine, Alborz University of Medical Sciences, Alborz, Iran
| | - Soheila Vasheghani Farahani
- Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Melika Gorgani
- Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States
| | - Nima Rezaei
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Dr. Qarib St, Keshavarz Blvd, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Mahzad Akbarpour
- Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States; Advanced Cellular Therapeutics Facility (ACTF), Hematopoietic Cellular Therapy Program, Section of Hematology & Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, United States.
| | - Ali-Akbar Delbandi
- Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
4
|
Villanueva‐Saz S, Giner J, Tobajas AP, Pérez MD, González‐Ramírez AM, Macías‐León J, González A, Verde M, Yzuel A, Hurtado‐Guerrero R, Pardo J, Santiago L, Paño‐Pardo JR, Ruíz H, Lacasta DM, Sánchez L, Marteles D, Gracia AP, Fernández A. Serological evidence of SARS-CoV-2 and co-infections in stray cats in Spain. Transbound Emerg Dis 2022; 69:1056-1064. [PMID: 33686768 PMCID: PMC8250530 DOI: 10.1111/tbed.14062] [Citation(s) in RCA: 50] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Revised: 02/09/2021] [Accepted: 03/05/2021] [Indexed: 12/12/2022]
Abstract
A new coronavirus known as SARS-CoV-2 emerged in Wuhan in 2019 and spread rapidly to the rest of the world causing the pandemic disease named coronavirus disease of 2019 (COVID-19). Little information is known about the impact this virus can cause upon domestic and stray animals. The potential impact of SARS-CoV-2 has become of great interest in cats due to transmission among domestic cats and the severe phenotypes described recently in a domestic cat. In this context, there is a public health warning that needs to be investigated in relation with the epidemiological role of this virus in stray cats. Consequently, in order to know the impact of the possible transmission chain, blood samples were obtained from 114 stray cats in the city of Zaragoza (Spain) and tested for SARS-CoV-2 and other selected pathogens susceptible to immunosuppression including Toxoplasma gondii, Leishmania infantum, feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV) from January to October 2020. Four cats (3.51%), based on enzyme-linked immunosorbent assay (ELISA) using the receptor binding domain (RBD) of Spike antigen, were seroreactive to SARS-CoV-2. T. gondii, L. infantum, FeLV and FIV seroprevalence was 12.28%, 16.67%, 4.39% and 19.30%, respectively. Among seropositive cats to SARS-CoV-2, three cats were also seropositive to other pathogens including antibodies detected against T. gondii and FIV (n = 1); T. gondii (n = 1); and FIV and L. infantum (n = 1). The subjects giving positive for SARS-CoV-2 were captured in urban areas of the city in different months: January 2020 (2/4), February 2020 (1/4) and July 2020 (1/4). This study revealed, for the first time, the exposure of stray cats to SARS-CoV-2 in Spain and the existence of concomitant infections with other pathogens including T. gondii, L. infantum and FIV, suggesting that immunosuppressed animals might be especially susceptible to SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Sergio Villanueva‐Saz
- Clinical Immunology Laboratory, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
- Department of Pharmacology and PhysiologyVeterinary FacultyUniversity of ZaragozaZaragozaSpain
- Instituto Agroalimentario de Aragón‐IA2 (Universidad de Zaragoza‐CITA)ZaragozaSpain
| | - Jacobo Giner
- Clinical Immunology Laboratory, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
- Deparment of Animal Pathology, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - Ana Pilar Tobajas
- Instituto Agroalimentario de Aragón‐IA2 (Universidad de Zaragoza‐CITA)ZaragozaSpain
- Department of Animal Production and Sciences of the Food, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - María Dolores Pérez
- Instituto Agroalimentario de Aragón‐IA2 (Universidad de Zaragoza‐CITA)ZaragozaSpain
- Department of Animal Production and Sciences of the Food, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - Andrés Manuel González‐Ramírez
- Institute for Biocomputation and Physics of Complex Systems (BIFI)Edificio I+DCampus Rio EbroUniversity of ZaragozaZaragozaSpain
| | - Javier Macías‐León
- Instituto Agroalimentario de Aragón‐IA2 (Universidad de Zaragoza‐CITA)ZaragozaSpain
| | - Ana González
- Deparment of Animal Pathology, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - Maite Verde
- Clinical Immunology Laboratory, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
- Instituto Agroalimentario de Aragón‐IA2 (Universidad de Zaragoza‐CITA)ZaragozaSpain
- Deparment of Animal Pathology, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - Andrés Yzuel
- Clinical Immunology Laboratory, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - Ramón Hurtado‐Guerrero
- Institute for Biocomputation and Physics of Complex Systems (BIFI)Edificio I+DCampus Rio EbroUniversity of ZaragozaZaragozaSpain
- Aragon I+D Foundation (ARAID)ZaragozaSpain
- Laboratorio de Microscopías Avanzada (LMA)Edificio I+D, Campus Rio EbroUniversity of ZaragozaZaragozaSpain
- Copenhagen Center for GlycomicsCopenhagenDenmark
- Department of Cellular and Molecular MedicineSchool of DentistryUniversity of CopenhagenCopenhagenDenmark
| | - Julián Pardo
- Aragon I+D Foundation (ARAID)ZaragozaSpain
- Aragon Health Research Institute (IIS Aragón)ZaragozaSpain
- Department of MicrobiologyPediatrics, Radiology and Public HealthZaragoza University of ZaragozaZaragozaSpain
| | | | - José Ramón Paño‐Pardo
- Aragon Health Research Institute (IIS Aragón)ZaragozaSpain
- Infectious Disease DepartmentUniversity Hospital Lozano BlesaZaragozaSpain
| | - Héctor Ruíz
- Deparment of Animal Pathology, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - Delia María Lacasta
- Instituto Agroalimentario de Aragón‐IA2 (Universidad de Zaragoza‐CITA)ZaragozaSpain
- Deparment of Animal Pathology, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - Lourdes Sánchez
- Instituto Agroalimentario de Aragón‐IA2 (Universidad de Zaragoza‐CITA)ZaragozaSpain
- Department of Animal Production and Sciences of the Food, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - Diana Marteles
- Clinical Immunology Laboratory, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - Ana Pilar Gracia
- Instituto Agroalimentario de Aragón‐IA2 (Universidad de Zaragoza‐CITA)ZaragozaSpain
- Department of Animal Production and Sciences of the Food, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| | - Antonio Fernández
- Clinical Immunology Laboratory, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
- Instituto Agroalimentario de Aragón‐IA2 (Universidad de Zaragoza‐CITA)ZaragozaSpain
- Deparment of Animal Pathology, Veterinary FacultyUniversity of ZaragozaZaragozaSpain
| |
Collapse
|
5
|
Shaik FB, Swarnalatha K, Mohan M, Thomas A, Chikati R, Sandeep G, Maddu N. Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS CoV-2 main protease (Mpro) and 3C-like protease for COVID-19 treatment. CLINICAL NUTRITION OPEN SCIENCE 2022; 42:62-72. [PMID: 35106518 PMCID: PMC8795779 DOI: 10.1016/j.nutos.2021.12.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 12/30/2021] [Indexed: 11/29/2022] Open
Abstract
OBJECTIVES Coronaviruses are globally emerging viruses that threaten our health care systems and have become a popular pandemic around the world. This causes a sudden rise in positive coronavirus cases and related deaths to occur worldwide, representing a significant health hazard to humans and the economy. METHODS We examined predominantly catechins of green tea include epigallocatechin-3-gallate (EGCG), epicatechin-3-gallate (ECG), and drugs of chloroquine (CQ), and hydroxychloroquine (HCQ) appearing to reveal anti-viral activities. Data were collected from PubMed, Google Scholar, and Science Direct databases. To investigate the role of antiviral effects (CQ and HCQ), green tea catechins, beneficial use of convalescent plasma; covaxin in COVID-19 patients faced a dangerous healthiness issue. Computational docking analysis has been used for this purpose. RESULTS The lead compounds are EGCG and ECG act as potential inhibitors bind to the active site region of the HKU4-CoV 3CL protease and M-Pro protease enzymes of coronavirus. Conclusions: SARS-COV-2 is a pathogen of substantial vigour concern and the review unveils the role of catechins associated with many viral diseases. We suggested that the function of green tea catechins, novel drugs of CQ, and HCQ exhibit antiviral activities against positive-sense single-stranded RNA viruses (CoVs).
Collapse
Affiliation(s)
- Fareeda Begum Shaik
- Department of Biochemistry, Sri Krishnadevaraya University, Anantapur, 515003, A.P. India
| | - K. Swarnalatha
- Department of Biochemistry, Sri Krishnadevaraya University, Anantapur, 515003, A.P. India
| | | | - Anu Thomas
- Department of Nursing, Banaswadi College of Nursing, Bangalore, Karnataka, India
| | - Rajasekhar Chikati
- Department of Biochemistry, Yogivemana University, Kadapa, 516005, A.P. India
| | - G. Sandeep
- Division of Molecular Biology, Department of Zoology, Sri Venkateswara University, Tirupati, 517502, A.P, India
| | - Narendra Maddu
- Department of Biochemistry, Sri Krishnadevaraya University, Anantapur, 515003, A.P. India,Corresponding author. Department of Biochemistry, Sri Krishnadevaraya University, Ananthapuramu, 515003, Andhra Pradesh, India. Tel.: +91 9441983797
| |
Collapse
|
6
|
Sharma A, Kontodimas K, Bosmann M. Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19. Front Med (Lausanne) 2021; 8:648005. [PMID: 34150793 PMCID: PMC8211875 DOI: 10.3389/fmed.2021.648005] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Accepted: 05/04/2021] [Indexed: 12/15/2022] Open
Abstract
The SARS-CoV-2 virus is causing devastating morbidity and mortality worldwide. Nanomedicine approaches have a high potential to enhance conventional diagnostics, drugs and vaccines. In fact, lipid nanoparticle/mRNA vaccines are already widely used to protect from COVID-19. In this review, we present an overview of the taxonomy, structure, variants of concern, epidemiology, pathophysiology and detection methods of SARS-CoV-2. The efforts of repurposing, tailoring, and adapting pre-existing medications to battle COVID-19 and the state of vaccine developments are presented. Next, we discuss the broad concepts and limitations of how nanomedicine could address the COVID-19 threat. Nanomaterials are particles in the nanometer scale (10-100 nm) which possess unique properties related to their size, polarity, structural and chemical composition. Nanoparticles can be composed of precious metals (copper, silver, gold), inorganic materials (graphene, silicon), proteins, carbohydrates, lipids, RNA/DNA, or conjugates, combinations and polymers of all of the aforementioned. The advanced biochemical features of these nanoscale particles allow them to directly interact with virions and irreversibly disrupt their structure, which can render a virus incapable of replicating within the host. Virus-neutralizing coats and surfaces impregnated with nanomaterials can enhance personal protective equipment, hand sanitizers and air filter systems. Nanoparticles can enhance drug-based therapies by optimizing uptake, stability, target cell-specific delivery, and magnetic properties. In fact, recent studies have highlighted the potential of nanoparticles in different aspects of the fight against SARS-CoV-2, such as enhancing biosensors and diagnostic tests, drug therapies, designing new delivery mechanisms, and optimizing vaccines. This article summarizes the ongoing research on diagnostic strategies, treatments, and vaccines for COVID-19, while emphasizing the potential of nanoparticle-based pharmaceuticals and vaccines.
Collapse
Affiliation(s)
- Arjun Sharma
- Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA, United States
- Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Konstantinos Kontodimas
- Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA, United States
| | - Markus Bosmann
- Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA, United States
- Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| |
Collapse
|
7
|
Peng HT, Rhind SG, Beckett A. Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis. JMIR Public Health Surveill 2021; 7:e25500. [PMID: 33825689 PMCID: PMC8245055 DOI: 10.2196/25500] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 02/19/2021] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND The COVID-19 pandemic, caused by a novel coronavirus termed SARS-CoV-2, has spread quickly worldwide. Convalescent plasma (CP) obtained from patients following recovery from COVID-19 infection and development of antibodies against the virus is an attractive option for either prophylactic or therapeutic treatment, since antibodies may have direct or indirect antiviral activities and immunotherapy has proven effective in principle and in many clinical reports. OBJECTIVE We seek to characterize the latest advances and evidence in the use of CP for COVID-19 through a systematic review and quantitative analysis, identify knowledge gaps in this setting, and offer recommendations and directives for future research. METHODS PubMed, Web of Science, and Embase were continuously searched for studies assessing the use of CP for COVID-19, including clinical studies, commentaries, reviews, guidelines or protocols, and in vitro testing of CP antibodies. The screening process and data extraction were performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Quality appraisal of all clinical studies was conducted using a universal tool independent of study designs. A meta-analysis of case-control and randomized controlled trials (RCTs) was conducted using a random-effects model. RESULTS Substantial literature has been published covering various aspects of CP therapy for COVID-19. Of the references included in this review, a total of 243 eligible studies including 64 clinical studies, 79 commentary articles, 46 reviews, 19 guidance and protocols, and 35 in vitro testing of CP antibodies matched the criteria. Positive results have been mostly observed so far when using CP for the treatment of COVID-19. There were remarkable heterogeneities in the CP therapy with respect to patient demographics, donor antibody titers, and time and dose of CP administration. The studies assessing the safety of CP treatment reported low incidence of adverse events. Most clinical studies, in particular case reports and case series, had poor quality. Only 1 RCT was of high quality. Randomized and nonrandomized data were found in 2 and 11 studies, respectively, and were included for meta-analysis, suggesting that CP could reduce mortality and increase viral clearance. Despite promising pilot studies, the benefits of CP treatment can only be clearly established through carefully designed RCTs. CONCLUSIONS There is developing support for CP therapy, particularly for patients who are critically ill or mechanically ventilated and resistant to antivirals and supportive care. These studies provide important lessons that should inform the planning of well-designed RCTs to generate more robust knowledge for the efficacy of CP in patients with COVID-19. Future research is necessary to fill the knowledge gap regarding prevention and treatment for patients with COVID-19 with CP while other therapeutics are being developed.
Collapse
Affiliation(s)
- Henry T Peng
- Defence Research and Development Canada, Toronto Research Centre, Toronto, ON, Canada
| | - Shawn G Rhind
- Defence Research and Development Canada, Toronto Research Centre, Toronto, ON, Canada
| | - Andrew Beckett
- St. Michael's Hospital, Toronto, ON, Canada
- Royal Canadian Medical Services, Ottawa, ON, Canada
| |
Collapse
|
8
|
Barreira DF, Lourenço RA, Calisto R, Moreira-Gonçalves D, Santos LL, Videira PA. Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021; 8:660688. [PMID: 33889590 PMCID: PMC8055850 DOI: 10.3389/fmed.2021.660688] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 03/09/2021] [Indexed: 01/08/2023] Open
Abstract
Background: The coronavirus disease (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), prompted a global health crisis, with no available specific treatments. Convalescent plasma (CP) with neutralizing antibodies could be a promising therapeutic approach to reduce mortality. Objectives: To evaluate the therapeutic potential of CP for COVID-19 and to assess its safety and efficacy in reducing the patients' mortality. Methods: We retrieved clinical trial references from multiple Databases (e.g., PubMed, B-On, SCOPUS), for complete studies until November 26th 2020. We included Randomized controlled trials (RCT) and controlled non-randomized trials (CNRT), that assessed the efficacy of CP to treat hospitalized COVID-19 patients. Trials were included regardless of concomitant medications in the intervention's arms. Eleven trials met our eligibility criteria. This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We defined a methodological protocol to extract and evaluate all pertinent baseline demographics and interventions' characteristics from trials. The primary outcomes were the safety profile of CP, measured by the type, frequency and severity of adverse events, and CP effectiveness in reducing mortality, measured by the number of deaths registered for this therapy. Results: We assessed 11 trials (5 RCT and 6 CNRT) with 3,098 participants, of whom 923 patients were treated with CP. Only 32 (3.5%) of the treated patients suffered adverse events (from which 9.4% serious transfusion-related adverse events). The overall mortality rates were significantly decreased by CP administration {risk ratio (RR) 0.71, p = 0.005, 95% confidence interval (Cl) [0.57-0.90]}, with low heterogeneity. In the sub-analysis by period of transfusion, CP transfusion within a week of hospitalization contributed to diminished mortality rate (RR = 0.71, p = 0.03, 95%Cl [0.53-0.96]). CP therapy also led to significantly reduced viral loads at 72 h after transfusion (RR = 0.61, p = 0.04, 95%Cl [0.38-0.98]), despite high heterogeneity due to disease severity. Conclusion: This meta-analysis established CP as a safe and potentially effective therapy for COVID-19, decreasing the mortality rates and promoting a swift viral clearance. Further studies are necessary to provide stronger evidence.
Collapse
Affiliation(s)
- Daniela Ferreira Barreira
- Department of Life Sciences, Applied Molecular Biosciences Unit, Faculdade de Ciências e Tecnologia da Universidade Nova De Lisboa, Caparica, Portugal
| | - Rita Adubeiro Lourenço
- Department of Life Sciences, Applied Molecular Biosciences Unit, Faculdade de Ciências e Tecnologia da Universidade Nova De Lisboa, Caparica, Portugal
| | - Rita Calisto
- Portuguese Institute of Oncology Francisco Gentil, Porto, Portugal
- Cancer Epidemiology Group, Portuguese Institute of Oncology Porto Research Centre (CI-IPOP), Portuguese Institute of Oncology Francisco Gentil, Porto, Portugal
| | - Daniel Moreira-Gonçalves
- Research Centre in Physical Activity, Health and Leisure, Faculdade de Desporto, Universidade do Porto, Porto, Portugal
| | - Lúcio Lara Santos
- Experimental Pathology and Therapeutics Group, Research Center, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal
- Surgical Oncology Department, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal
| | - Paula Alexandra Videira
- Department of Life Sciences, Applied Molecular Biosciences Unit, Faculdade de Ciências e Tecnologia da Universidade Nova De Lisboa, Caparica, Portugal
- Congenital Disorders of Glycosylation Professionals and Patient Associations International Network (CDG and Allies-PPAIN), Lisboa, Portugal
| |
Collapse
|
9
|
Santiago L, Uranga-Murillo I, Arias M, González-Ramírez AM, Macías-León J, Moreo E, Redrado S, García-García A, Taleb V, Lira-Navarrete E, Hurtado-Guerrero R, Aguilo N, del Mar Encabo-Berzosa M, Hidalgo S, Galvez EM, Ramirez-Labrada A, de Miguel D, Benito R, Miranda P, Fernández A, Domingo JM, Serrano L, Yuste C, Villanueva-Saz S, Paño-Pardo JR, Pardo J. Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. BIOLOGY 2021; 10:208. [PMID: 33801808 PMCID: PMC8001978 DOI: 10.3390/biology10030208] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Revised: 03/01/2021] [Accepted: 03/06/2021] [Indexed: 12/22/2022]
Abstract
Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.
Collapse
Affiliation(s)
- Llipsy Santiago
- Biomedical Research Centre of Aragón (CIBA), Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain; (L.S.); (I.U.-M.); (S.H.); (D.d.M.); (R.B.)
| | - Iratxe Uranga-Murillo
- Biomedical Research Centre of Aragón (CIBA), Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain; (L.S.); (I.U.-M.); (S.H.); (D.d.M.); (R.B.)
| | - Maykel Arias
- Instituto de Carboquímica (ICB), Consejo Superior de Investigaciones Científicas (CSIC), 50018 Zaragoza, Spain; (M.A.); (S.R.); (E.M.G.)
| | - Andrés Manuel González-Ramírez
- Institute for Biocomputation and Physics of Complex Systems (BIFI), Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, 50018 Zaragoza, Spain; (A.M.G.-R.); (J.M.-L.); (A.G.-G.); (V.T.); (E.L.-N.); (R.H.-G.)
| | - Javier Macías-León
- Institute for Biocomputation and Physics of Complex Systems (BIFI), Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, 50018 Zaragoza, Spain; (A.M.G.-R.); (J.M.-L.); (A.G.-G.); (V.T.); (E.L.-N.); (R.H.-G.)
| | - Eduardo Moreo
- Department Microbiology, Preventive Medicine and Public Health, University of Zaragoza, 50009 Zaragoza, Spain; (E.M.); (N.A.)
| | - Sergio Redrado
- Instituto de Carboquímica (ICB), Consejo Superior de Investigaciones Científicas (CSIC), 50018 Zaragoza, Spain; (M.A.); (S.R.); (E.M.G.)
| | - Ana García-García
- Institute for Biocomputation and Physics of Complex Systems (BIFI), Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, 50018 Zaragoza, Spain; (A.M.G.-R.); (J.M.-L.); (A.G.-G.); (V.T.); (E.L.-N.); (R.H.-G.)
| | - Víctor Taleb
- Institute for Biocomputation and Physics of Complex Systems (BIFI), Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, 50018 Zaragoza, Spain; (A.M.G.-R.); (J.M.-L.); (A.G.-G.); (V.T.); (E.L.-N.); (R.H.-G.)
| | - Erandi Lira-Navarrete
- Institute for Biocomputation and Physics of Complex Systems (BIFI), Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, 50018 Zaragoza, Spain; (A.M.G.-R.); (J.M.-L.); (A.G.-G.); (V.T.); (E.L.-N.); (R.H.-G.)
| | - Ramón Hurtado-Guerrero
- Institute for Biocomputation and Physics of Complex Systems (BIFI), Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, 50018 Zaragoza, Spain; (A.M.G.-R.); (J.M.-L.); (A.G.-G.); (V.T.); (E.L.-N.); (R.H.-G.)
- Aragon I+D Foundation (ARAID), 50018 Zaragoza, Spain
- Laboratorio de Microscopías Avanzada (LMA), Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, 50018 Zaragoza, Spain
- Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, School of Dentistry, University of Copenhagen, DK-2200 Copenhagen, Denmark
| | - Nacho Aguilo
- Department Microbiology, Preventive Medicine and Public Health, University of Zaragoza, 50009 Zaragoza, Spain; (E.M.); (N.A.)
| | | | - Sandra Hidalgo
- Biomedical Research Centre of Aragón (CIBA), Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain; (L.S.); (I.U.-M.); (S.H.); (D.d.M.); (R.B.)
| | - Eva M. Galvez
- Instituto de Carboquímica (ICB), Consejo Superior de Investigaciones Científicas (CSIC), 50018 Zaragoza, Spain; (M.A.); (S.R.); (E.M.G.)
| | - Ariel Ramirez-Labrada
- Unidad de Nanotoxicología e Inmunotoxicología (UNATI), Biomedical Research Centre of Aragón (CIBA), Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain;
| | - Diego de Miguel
- Biomedical Research Centre of Aragón (CIBA), Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain; (L.S.); (I.U.-M.); (S.H.); (D.d.M.); (R.B.)
| | - Rafael Benito
- Biomedical Research Centre of Aragón (CIBA), Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain; (L.S.); (I.U.-M.); (S.H.); (D.d.M.); (R.B.)
- Department Microbiology, Preventive Medicine and Public Health, University of Zaragoza, 50009 Zaragoza, Spain; (E.M.); (N.A.)
- Servicio de Microbiología, Hospital Clinico Universitario Lozano Blesa, 50009 Zaragoza, Spain
| | - Patricia Miranda
- Banco de Sangre y Tejidos de Aragón, 50009 Zaragoza, Spain; (P.M.); (J.M.D.)
| | - Antonio Fernández
- Department Animal Pathology, University of Zaragoza, 50013 Zaragoza, Spain;
| | - José María Domingo
- Banco de Sangre y Tejidos de Aragón, 50009 Zaragoza, Spain; (P.M.); (J.M.D.)
| | - Laura Serrano
- Servicio de Prevención de Riesgos Laborales, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain; (L.S.); (C.Y.)
| | - Cristina Yuste
- Servicio de Prevención de Riesgos Laborales, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain; (L.S.); (C.Y.)
| | - Sergio Villanueva-Saz
- Department Pharmacology and Physiology, University of Zaragoza, 50013 Zaragoza, Spain;
| | - José Ramón Paño-Pardo
- Biomedical Research Centre of Aragón (CIBA), Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain; (L.S.); (I.U.-M.); (S.H.); (D.d.M.); (R.B.)
- Servicio de Enfermedades Infecciosas, Hospital Clinico Universitario Lozano Blesa, 50009 Zaragoza, Spain
| | - Julián Pardo
- Biomedical Research Centre of Aragón (CIBA), Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain; (L.S.); (I.U.-M.); (S.H.); (D.d.M.); (R.B.)
- Department Microbiology, Preventive Medicine and Public Health, University of Zaragoza, 50009 Zaragoza, Spain; (E.M.); (N.A.)
- Aragon I+D Foundation (ARAID), 50018 Zaragoza, Spain
- Centro de Investigación Biomédicaen Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 50018 Madrid, Spain
| |
Collapse
|
10
|
Sweeney JM, Barouqa M, Krause GJ, Gonzalez-Lugo JD, Rahman S, Gil MR. Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients. TH OPEN 2021; 5:e89-e103. [PMID: 33709050 PMCID: PMC7943318 DOI: 10.1055/s-0041-1723784] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2020] [Accepted: 12/29/2020] [Indexed: 01/08/2023] Open
Abstract
The causes of coagulopathy associated with coronavirus disease 2019 (COVID-19) are poorly understood. We aimed to investigate the relationship between von Willebrand factor (VWF) biomarkers, intravascular hemolysis, coagulation, and organ damage in COVID-19 patients and study their association with disease severity and mortality. We conducted a retrospective study of 181 hospitalized COVID-19 patients randomly selected with balanced distribution of survivors and nonsurvivors. Patients who died had significantly lower ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity, significantly elevated lactate dehydrogenase levels, significantly increased shistocyte/RBC fragment counts, and significantly elevated VWF antigen and activity levels compared with patients discharged alive. These biomarkers correlate with markedly elevated D-dimers. Additionally, only 30% of patients who had an ADAMTS13 activity level of less than 43% on admission survived, yet 60% of patients survived who had an ADAMTS13 activity level of greater than 43% on admission. In conclusion, COVID-19 may present with low ADAMTS13 activity in a subset of hospitalized patients. Presence of schistocytes/RBC fragment and elevated D-dimer on admission may warrant a work-up for ADAMTS13 activity and VWF antigen and activity levels. These findings indicate the need for future investigation to study the relationship between endothelial and coagulation activation and the efficacy of treatments aimed at prevention and/or amelioration of microangiopathy in COVID-19.
Collapse
Affiliation(s)
- Joseph M Sweeney
- Department Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, New York, United States
| | - Mohammad Barouqa
- Department of Pathology Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States
| | - Gregory J Krause
- Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, United States.,Institute of Aging Studies, Albert Einstein College of Medicine, Bronx, New York, United States
| | - Jesus D Gonzalez-Lugo
- Division of Hematology, Department of Medical Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, United States
| | - Shafia Rahman
- Division of Hematology, Department of Medical Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, United States
| | - Morayma Reyes Gil
- Department of Pathology Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States
| |
Collapse
|
11
|
Naik AQ, Zafar T, Shrivastava VK. The Perspective of Coronavirus Disease Outbreak: Epidemiology, Transmission, and Possible Treatment. Vector Borne Zoonotic Dis 2021; 21:78-85. [DOI: 10.1089/vbz.2020.2678] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Affiliation(s)
- Ab Qayoom Naik
- Laboratory of Endocrinology, Department of Biosciences, Barkatullah University, Bhopal, India
| | - Tabassum Zafar
- Laboratory of Endocrinology, Department of Biosciences, Barkatullah University, Bhopal, India
| | - Vinoy K. Shrivastava
- Laboratory of Endocrinology, Department of Biosciences, Barkatullah University, Bhopal, India
| |
Collapse
|
12
|
Wang KY, Shah P, Pierce M. Convalescent plasma for COVID-19 complicated by ARDS due to TRALI. BMJ Case Rep 2021; 14:e239762. [PMID: 33509890 PMCID: PMC10577747 DOI: 10.1136/bcr-2020-239762] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/13/2021] [Indexed: 12/28/2022] Open
Abstract
Convalescent plasma, which contains antibodies from recovered individuals, has been used as an effective treatment for infectious diseases in the past and is currently being used as a potential treatment option for COVID-19. Multiple studies have reported this treatment to be safe. We report a case of a patient who developed acute respiratory distress syndrome (ARDS) with features suggestive of transfusion-related acute lung injury after being treated with convalescent plasma for COVID-19. We emphasise the need to be aware of the potential risk of transfusion reactions and disease worsening with convalescent plasma administration and to weigh the risk and benefits of this therapy before administration to patients and propose that further study be done regarding the potential risks of convalescent plasma.
Collapse
Affiliation(s)
- Kevin Y Wang
- Internal Medicine, Northwell Health, Great Neck, New York, USA
| | - Pratik Shah
- Internal Medicine, Northwell Health, Great Neck, New York, USA
| | - Matthew Pierce
- Internal Medicine, Northwell Health, Great Neck, New York, USA
| |
Collapse
|
13
|
Pau AK, Aberg J, Baker J, Belperio PS, Coopersmith C, Crew P, Grund B, Gulick RM, Harrison C, Kim A, Lane HC, Masur H, Sheikh V, Singh K, Yazdany J, Tebas P. Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med 2021; 174:93-95. [PMID: 32976026 PMCID: PMC7556653 DOI: 10.7326/m20-6448] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
In the United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being tested in randomized placebo-controlled clinical trials. Treatment of individual patients with COVID-19 with convalescent plasma outside such trials is also now permitted through U.S. Food and Drug Administration Emergency Use Authorization. Here, members of the National Institutes of Health COVID-19 Treatment Guidelines Panel provide their views regarding use of convalescent plasma for treating COVID-19.
Collapse
Affiliation(s)
- Alice K Pau
- National Institutes of Health, Bethesda, Maryland (A.K.P., P.C., H.C.L., H.M., K.S.)
| | - Judith Aberg
- Icahn School of Medicine at Mount Sinai, New York, New York (J.A.)
| | - Jason Baker
- Hennepin Healthcare/University of Minnesota, Minneapolis, Minnesota (J.B.)
| | | | | | - Page Crew
- National Institutes of Health, Bethesda, Maryland (A.K.P., P.C., H.C.L., H.M., K.S.)
| | - Birgit Grund
- University of Minnesota, Minneapolis, Minnesota (B.G.)
| | - Roy M Gulick
- Weill Cornell Medicine, New York, New York (R.M.G.)
| | | | - Arthur Kim
- Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts (A.K.)
| | - H Clifford Lane
- National Institutes of Health, Bethesda, Maryland (A.K.P., P.C., H.C.L., H.M., K.S.)
| | - Henry Masur
- National Institutes of Health, Bethesda, Maryland (A.K.P., P.C., H.C.L., H.M., K.S.)
| | - Virginia Sheikh
- U.S. Food and Drug Administration, Silver Spring, Maryland (V.S.)
| | - Kanal Singh
- National Institutes of Health, Bethesda, Maryland (A.K.P., P.C., H.C.L., H.M., K.S.)
| | - Jinoos Yazdany
- University of California, San Francisco, San Francisco, California (J.Y.)
| | - Pablo Tebas
- University of Pennsylvania, Philadelphia, Pennsylvania (P.T.)
| | | |
Collapse
|
14
|
Sahu KK, Mishra AK, Raturi M, Lal A. Current Perspectives of convalescent plasma therapy in COVID-19. ACTA BIO-MEDICA : ATENEI PARMENSIS 2020; 91:e2020175. [PMID: 33525227 PMCID: PMC7927533 DOI: 10.23750/abm.v91i4.10681] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Accepted: 09/27/2020] [Indexed: 02/07/2023]
Abstract
The outbreak of the coronavirus disease 2019 (COVID-19) has posed an unprecedented challenge to the health care communities across the globe. As of December 2020, a total of 69,874,432 confirmed COVID-19 cases with 1,553,000 deaths have been reported. Different regions of the world have reported varying intensity of COVID-19 severity. The disease burden for COVID-19 depends on multiple factors like the local infection rate, susceptible population, mortality rate, and so on. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. As of today, there is a lack of definitive treatment options for COVID-19 pneumonia. In search of alternative options, few drugs are being tested for their efficacy and repurposing. Preliminary reports have shown positive outcomes with Remdesivir and tocilizumab, but this needs further confirmation. Recently, the therapeutic application of Convalescent Plasma therapy in critically ill patients suffering from COVID-19 has gained momentum. We hereby discuss the convalescent plasma as a potential therapeutic option, its challenges of finding the ideal donors, transfusion medicine responsibilities, and the current global experience with its use. (www.actabiomedica.it)
Collapse
Affiliation(s)
- Kamal Kant Sahu
- Department of Medicine Saint Vincent Hospital Worcester, MA.
| | | | - Manish Raturi
- Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Jolly Grant Dehradun, Uttarakhand, India. .
| | | |
Collapse
|
15
|
Fischer JC, Zänker K, van Griensven M, Schneider M, Kindgen-Milles D, Knoefel WT, Lichtenberg A, Tamaskovics B, Djiepmo-Njanang FJ, Budach W, Corradini S, Ganswindt U, Häussinger D, Feldt T, Schelzig H, Bojar H, Peiper M, Bölke E, Haussmann J, Matuschek C. Correction to: The role of passive immunization in the age of SARS-CoV-2: an update. Eur J Med Res 2020; 25:53. [PMID: 33126916 PMCID: PMC7596629 DOI: 10.1186/s40001-020-00449-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- Johannes C Fischer
- Institute for Transplant Diagnostics and Cell Therapeutics, Heinrich Heine University, Düsseldorf, Germany
| | - Kurt Zänker
- The Nanjing Han & Zaenker Cancer Institute, Nanjing and Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing Tech University, Jiangsu, China
| | - Martijn van Griensven
- MERLN Institute for Technology-Inspired Regenerative Medicine, Department cBITE, Maastricht University, Maastricht, The Netherlands
| | - Marion Schneider
- Department of Experimental Anesthesiology, University of Ulm, Ulm, Germany
| | - Detlef Kindgen-Milles
- Department of Anesthesiology and Intensive Care Medicine, Heinrich Heine University, Düsseldorf, Germany
| | | | - Artur Lichtenberg
- Department of Cardiac Surgery, Heinrich Heine University, Düsseldorf, Germany
| | - Balint Tamaskovics
- Department of Radiation Oncology, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
| | | | - Wilfried Budach
- Department of Radiation Oncology, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Stefanie Corradini
- Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany
| | - Ute Ganswindt
- Department of Radiation Oncology, Innsbruck, Austria
| | - Dieter Häussinger
- Clinic of Gastroenterology, Hepatology und Infectious Diseases, Heinrich Heine University, Düsseldorf, Germany
| | - Torsten Feldt
- Clinic of Gastroenterology, Hepatology und Infectious Diseases, Heinrich Heine University, Düsseldorf, Germany
| | - Hubert Schelzig
- Department of Vascular Surgery, Heinrich Heine University, Düsseldorf, Germany
| | - Hans Bojar
- NEXTGEN ONCOLOGY GROUP, Düsseldorf, Germany
| | | | - Edwin Bölke
- Department of Radiation Oncology, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany.
| | - Jan Haussmann
- Department of Radiation Oncology, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Christiane Matuschek
- Department of Radiation Oncology, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
| |
Collapse
|
16
|
Sweeney JM, Barouqa M, Krause GJ, Gonzalez-Lugo JD, Rahman S, Gil MR. Evidence for secondary thrombotic microangiopathy in COVID-19. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2020:2020.10.20.20215608. [PMID: 33106812 PMCID: PMC7587832 DOI: 10.1101/2020.10.20.20215608] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The causes of coagulopathy associated with COVID-19 disease are poorly understood. We aimed to investigate the relationship between markers of endothelial activation, intravascular hemolysis, coagulation, and organ damage in COVID-19 patients and study their association with disease severity and mortality. We conducted a retrospective study of 181 hospitalized COVID-19 patients randomly selected with equal distribution of survivors and non-survivors. Patients who died had significantly lower ADAMTS13 activity, significantly higher LDH, schistocytes and von Willebrand Factor levels compared to patients discharged alive. Only 30% of patients with an initial ADAMTS13 activity <43% survived vs. 60% with ADAMTS13 ≥43% who survived. In conclusion, COVID-19 may manifest as a TMA-like illness in a subset of hospitalized patients. Presence of schistocytes on admission may warrant a work-up for TMA. These findings indicate the need for future investigation to study the relationship between endothelial and coagulation activation and the efficacy of TMA treatments in COVID-19.
Collapse
Affiliation(s)
- Joseph M. Sweeney
- Department Physiology and Biophysics. Albert Einstein College of Medicine, Bronx, NY
| | - Mohammad Barouqa
- Department of Pathology Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - Gregory J. Krause
- Department of Developmental and Molecular Biology. Albert Einstein College of Medicine, Bronx, NY
- Institute of Aging Studies. Albert Einstein College of Medicine, Bronx, NY
| | - Jesus D. Gonzalez-Lugo
- Division of Hematology, Department of Medical Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
| | - Shafia Rahman
- Division of Hematology, Department of Medical Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
| | - Morayma Reyes Gil
- Department of Pathology Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| |
Collapse
|
17
|
K. Konstantinidou S, P. Papanastasiou I. Repurposing current therapeutic regimens against SARS-CoV-2 (Review). Exp Ther Med 2020; 20:1845-1855. [PMID: 32782493 PMCID: PMC7401312 DOI: 10.3892/etm.2020.8905] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 06/02/2020] [Indexed: 12/18/2022] Open
Abstract
The recent coronavirus outbreak has spread worldwide, with the exception of Antarctica, causing serious social and economic disruption. All disciplines of the science community are driven to confront the impact of the COVID-19 pandemic, as currently, there is neither prophylactic nor therapeutic treatments available. Due to the urgency of the situation, various research strategies are ongoing, in order to evaluate the therapeutic efficacy of repurposed and experimental drugs. The present review presents the most promising repurposed regimens, which may be used for the treatment of COVID-19. The drugs/bioactive substances presented herein belong to diverse therapeutic classes, including antimalarial, cardioprotective, angiotensin-converting enzyme 2 inhibitors, antiviral, anti-inflammatory and antiparasitic drugs. Therapeutic perspectives of vaccination and passive immunization are also reviewed.
Collapse
Affiliation(s)
- Sofia K. Konstantinidou
- Oncology Unit, The Third Department of Medicine, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Ioannis P. Papanastasiou
- Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece
| |
Collapse
|